A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations

PI: Dr.ssa Arsela Prelaj 

This trial is testing MK-2870 in subject with non-small cell lung cancer (NSCLC) that cannot be treated surgically or by radiotherapy, or that has spread to other parts of the body. 

This trial will compare MK-2870 with docetaxel and pemetrexed. These drugs are standard chemotherapeutics for the treatment of advanced or metastatic NSCLC. 

Which drug you receive will depend on which group you are in.  

This trial have 2 groups:  

• Group 1: will receive MK-2870  
• Group 2: will receive docetaxel or pemetrexed